Fibrinogen-like protein 2 expression correlates with microthrombosis in rats with type 2 diabetic nephropathy

Journal of Biomedical Research

Volumn 25, Issue 2, 2011, Pages 120-127

  Su, Guanhua ^a   Liu, Kun ^a   Wang, Yan ^a   Wang, Jue ^a   Li, Xiaowei ^a   Li, Wenzhu ^a   Liao, Yuhua ^a   Wang, Zhaohui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Diabetic nephropathy; Factor ; Fibrinogen like protein 2; Microthrombosis; Tumor necrosis; Type 2 diabetes

Indexed keywords

FIBRINOGEN; FIBRINOGEN LIKE PROTEIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; KIDNEY DISEASE; KIDNEY ISCHEMIA; KIDNEY PARENCHYMA; MALE; MICROTHROMBUS; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES;

EID: 79955430745     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(11)60015-8     Document Type: Article

References (33)

1. Ritz E, Orth SR Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999, 341:1127-1133.
2. Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352:213-219.
3. Kanková K Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?. Proc Nutr Soc 2008, 67:60-74.
4. Schena FP, Gesualdo L Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005, 16(Suppl 1):S30--S303.
5. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H Glomerular hyperfiltration in experimental diabetes mellitus. J Am Soc Nephrol 1999, 10:2569-2576.
6. Ghanekar A, Mendicino M, Liu H, He W, Liu M, Zhong R, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004, 172:5693-5701.
7. Boeri D, Maiello M, Lorenzi M Increased prevalence of microthrombosis in retinal capillaries of diabetic individuals. Diabetes 2001, 50:1432-1439.
8. Levy GA, Liu M, Ding J, Yuwaraj S, Leibowitz J, Marsden PA, et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathology 2000, 156:1217-1225.
9. Chan CW, Chan MW, Liu M, Fung L, Cole EH, Leibowitz JL, et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol 2002, 168:5170-5177.
10. Marsden PA, Ning Q, Fung LS, Luo X, Chen Y, Mendicino M, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003, 112:58-66.
11. Mendicino M, Liu M, Ghanekar A, He W, Koscik C, Shalev I, et al. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation 2005, 112:248-256.
12. Clark DA, Foerster K, Fung L, He W, Lee L, Mendicino M, et al. The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. Mol Hum Reprod 2004, 10:99-108.
13. Knackstedt MK, Zenclussen AC, Hertwig K, Hagen E, Dudenhausen JW, Clark DA, et al. Th1 cytokines and the prothrombinase fgl2 in stress-triggered and inflammatory abortion. Am J Reprod Immunol 2003, 49:210-220.
14. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R, et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998, 47:663-668.
15. Doolittle RF The structure and evolution of vertebrate fibrinogen. Ann N Y Acad Sci 1983, 408:13-27.
16. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007, 92:4352-4358.
17. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Casale Monferrato Study, et al. Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 2005, 48:427-434.
18. Su K, Chen F, Yan WM, Zeng QL, Xu L, Xi D, et al. Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. World J Gastroenterol 2008, 14:5980-5989.
19. Liu H, Zhang L, Cybulsky M, Gorczynski R, Crookshank J, Manuel J, et al. Identification of the receptor for FGL2 and implications for susceptibility to mouse hepatitis virus (MHV-3)-induced fulminant hepatitis. Adv Exp Med Biol 2006, 581:421-425.
20. Guest CB, Park MJ, Johnson DR, Freund GG The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 2008, 13:5187-5194.
21. Fornoni A, Ijaz A, Tejada T, Lenz O Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 2008, 4:10-17.
22. Dhalla NS, Liu X, Panagia V, Takeda N Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998, 40:239-247.
23. Moller DE Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11:212-217.
24. Peraldi P, Spiegelman B TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998, 182:169-175.
25. Liu M, Mendicino M, Ning Q, Ghanekar A, He W, I McGilvray, et al. Cytokine-induced hepatic apoptosis is dependent on FGL2/fibroleukin: the role of Sp1/Sp3 and STAT1/PU.1 composite cis elements. J Immunol 2006, 176:7028-7038.
26. Hancock WW, Szaba FM, Berggren KN, Parent MA, Mullarky IK, Pearl J, et al. Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Natl Acad Sci USA 2004, 101:3005-3010.
27. Ning Q, Sun Y, Han M, Zhang L, Zhu C, Zhang W, et al. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol 2005, 174:7403-7411.
28. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 1996, 228:539-543.
29. Forbes JM, Coughlan MT, Cooper ME Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
30. Evans JL, Goldfine ID, Maddux BA, Grodsky GM Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
31. Noh H, King GL The role of protein kinase C activation in diabetic nephropathy. Kidney Int 2007, 72(Suppl):S49-S53.
32. Wolf G New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004, 34:785-796.
33. Remuzzi G, Benigni A, Remuzzi A Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288-296.